Publications

  1. Allyse M, Bombard Y, Isasi R, Michie M, Musunuru K, Ormond KE. What do we do now?: Responding to claims of germline gene editing in humans. Genet Med. 2019 Oct; 21 (10):2181-2183 Epub 2019 Mar 27
    View PubMed
  2. Skotko BG, Allyse MA, Bajaj K, Best RG, Klugman S, Leach M, Meredith S, Michie M, Stoll K, Gregg AR. Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. Genet Med. 2019 Oct; 21 (10):2285-2292 Epub 2019 Apr 03
    View PubMed
  3. Snure Beckman E, Deuitch N, Michie M, Allyse MA, Riggan KA, Ormond KE. Attitudes Toward Hypothetical Uses of Gene-Editing Technologies in Parents of People with Autosomal Aneuploidies. CRISPR J. 2019 Oct; 2 (5):324-330
    View PubMed
  4. Ormond KE, Bombard Y, Bonham VL, Hoffman-Andrews L, Howard H, Isasi R, Musunuru K, Riggan KA, Michie M, Allyse M. The clinical application of gene editing: ethical and social issues. Per Med. 2019 Jul; 16 (4):337-350 Epub 2019 July 23
    View PubMed
  5. Riggan KA, Collura CA, Pittock ST, Ruano R, Whitford KJ, Allyse M. Ethical considerations of maternal-fetal intervention in a twin pregnancy discordant for anomalies. J Matern Fetal Neonatal Med. 2019 Jun 20; 1-6 Epub 2019 June 20
    View PubMed
  6. Riggan KA, Sharp RR, Allyse M. Where Will We Draw the Line? Public Opinions of Human Gene Editing. Qual Health Res. 2019 May 5; 1049732319846867 Epub 2019 May 05
    View PubMed
  7. Riggan KA, Allyse M. 'Compassionate transfer': an alternative option for surplus embryo disposition. Hum Reprod. 2019 May 1; 34 (5):791-794
    View PubMed
  8. Michie M, Allyse M. Gene modification therapies: views of parents of people with Down syndrome. Genet Med. 2019 Feb; 21 (2):487-492 Epub 2018 June 21
    View PubMed
  9. Jaramillo C, Nyquist C, Riggan KA, Egginton J, Phelan S, Allyse M. Delivering the Diagnosis of Sex Chromosome Aneuploidy: Experiences and Preferences of Parents and Individuals. Clin Pediatr (Phila). 2018 Dec 5; 9922818817310 Epub 2018 Dec 05
    View PubMed
  10. Gammon BL, Jaramillo C, Riggan KA, Allyse M. Decisional regret in women receiving high risk or inconclusive prenatal cell-free DNA screening results. J Matern Fetal Neonatal Med. 2018 Oct 1; 1-7 Epub 2018 Oct 01
    View PubMed
  11. Allyse MA, Wick MJ. Noninvasive Prenatal Genetic Screening Using Cell-free DNA. JAMA. 2018 Aug 14; 320 (6):591-592
    View PubMed
  12. Gammon BL, Otto L, Wick M, Borowski K, Allyse M. Implementing Group Prenatal Counseling for Expanded Noninvasive Screening Options. J Genet Couns. 2018 Aug; 27 (4):894-901 Epub 2017 Dec 15
    View PubMed
  13. Allyse M. CRSPR/CAS 9 and Human Therapeutics Clinical Chemistry. July 2018; 64(8):1266-67.
  14. Farrell RM, Allyse MA. Key Ethical Issues in Prenatal Genetics: An Overview. Obstet Gynecol Clin North Am. 2018 Mar; 45 (1):127-141 Epub 2017 Dec 09
    View PubMed
  15. Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing. Mayo Clin Proc. 2018 Jan; 93 (1):113-120
    View PubMed
  16. Allyse M, Wick MJ. What do the new American College of Medical Genetics and Genomics (ACMG) guidelines mean for the provision of non-invasive prenatal genetic screening? J Obstet Gynaecol. 2017 Aug; 37 (6):795-798 Epub 2017 Apr 01
    View PubMed
  17. Stoll KA, Mackison A, Allyse MA, Michie M. Conflicts of interest in genetic counseling: acknowledging and accepting. Genet Med 2017 Aug; 19 (8):864-866 Epub 2017 Jan 26
    View PubMed
  18. Allyse M, Aypar U, Bonhomme N, Darilek S, Dougherty M, Farrell R, Grody W, Highsmith WE, Michie M, Nunes M, Otto L, Pabst R, Palomaki G, Runke C, Sharp RR, Skotko B, Stoll K, Wick M. Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide. J Womens Health (Larchmt). 2017 Jul; 26 (7):755-761 Epub 2017 Apr 07
    View PubMed
  19. Mozersky J, Ravitsky V, Rapp R, Michie M, Chandrasekharan S, Allyse M. Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context. Hastings Cent Rep. 2017 Mar; 47: (2)41-49.
    View PubMed
  20. Parham L, Michie M, Allyse M. Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues Current Genetic Medicine Reports.02/11/2017;
  21. Tilburt JC, Allyse M, Hafferty FW. The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? AMA J Ethics. 2017 Feb 01; 19 (2):199-206
    View PubMed
  22. Li G, Chandrasekharan S, Allyse M. "The Top Priority Is a Healthy Baby": Narratives of Health, Disability, and Abortion in Online Pregnancy Forum Discussions in the US and China. J Genet Couns. 2017 Feb; 26 (1):32-39 Epub 2016 June 09
    View PubMed
  23. Floyd E, Allyse MA, Michie M. Spanish- and English-Speaking Pregnant Women's Views on cfDNA and Other Prenatal Screening: Practical and Ethical Reflections. J Genet Couns. 2016 Oct; 25 (5):965-77 Epub 2016 Jan 07
    View PubMed
  24. Meredith S, Kaposy C, Miller VJ, Allyse M, Chandrasekharan S, Michie M, Prenatal Testing PAG Coalition. Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States. Prenat Diagn. 2016 Aug; 36 (8):714-9 Epub 2016 July 18
    View PubMed
  25. Gammon BL, Kraft SA, Michie M, Allyse M. "I think we've got too many tests!": Prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):334-342
    View PubMed
  26. Michie M, Kraft SA, Minear MA, Ryan RR, Allyse MA. Informed decision-making about prenatal cfDNA screening: An assessment of written materials. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):362-371 Epub 2016 Sept 13
    View PubMed
  27. Li G., Allyse M. Experiences of Mandarin-speaking and English-speaking women of undergoing non-invasive prenatal genetic screening. Ethics, Medicine and Public Health.2016;2:(3):372-82.
  28. Steinbach RJ, Allyse M, Michie M, Liu EY, Cho MK. "This lifetime commitment": Public conceptions of disability and noninvasive prenatal genetic screening. Am J Med Genet A. 2016 Feb; 170A (2):363-374 Epub 2015 Nov 14
    View PubMed
  29. Allyse M, Chandrasekharan S. Too much, too soon?: Commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond. Genet Med. 2015 Dec; 17 (12):958-61 Epub 2015 Mar 19
    View PubMed
  30. Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annu Rev Genomics Hum Genet. 2015; 16:369-98.
    View PubMed
  31. Allyse M, Sayres LC, Michie M, Goodspeed T, Cho M. Don't want no risk, don't want no problems: Public understandings of the risks and benefits of novel prenatal technologies in the United States. AJOB Empirical Bioethics.2015;6:(1):5-20.
    View PubMed
  32. Sayres LC, Allyse M, Goodspeed T, Cho MK. Demographic and Experiential Predictors of Public Attitudes towards Cell-Free Fetal DNA Journal of Genetic Counseling.0;23:(6):957-67.
    View PubMed
  33. Chandresekharan S, Minear M, Hung A, Allyse M. Noninvasive prenatal testing goes global. Science Translational Medicine.2014;
  34. Allyse M, Sayres LC, Goodspeed T, Cho MK. Attitudes Towards Non-Invasive Prenatal Testing Among US Adults of Reproductive Age Journal of Perinatology. 2014 March 6.
  35. Allyse M, Minear M, Berson E, Rote M, Sidhar S, Hung A, Chandresekharan S. Non-Invasive Prenatal Testing: A review of international implementation and challenges International Journal of Women's Health. 2014.
  36. Constantine M, Allyse M, Wall M, De Vries R, Rockwood TH. Imperfect Informed Consent in Non-Invasive Prenatal Testing: Lessons from the quad screen. Clinical Ethics.2013;
  37. Berryessa C, Martinex-Martin N, Allyse M. Ethical, Legal and Social Issues Surrounding Research on Genetic Contributions to Anti-Social Behavior Aggression and Violent Behavior.2013;605-610.
  38. Allyse M, Sayres LC, Havard M, Norton ME, Hudgins L, Taylor J, King JS, Cho MK, Greely HT, Magnus D, Ormond KE. Best Practices in the Provision of Non-Invasive Prenatal Diagnosis Prenatal Diagnosis. 2013:656-61.
  39. Allyse M, Michie M. Not-so-incidental-findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing Trends in Biotechnology. 2013:439-41.
  40. Allyse M. 23andMe, We and You: Direct-to-consumer genetics, intellectual property and informed consent Trends in Biotechnology. 2013:68-69.
  41. Goodspeed T, Allyse M, Sayres L, Norton ME, Cho MK. Translating Cell-Free Fetal DNA Trends in Biotechnology.2013;7-9.
  42. Allyse M, Sayres L, Norton M, King JS, Cho MK. Cell-free fetal DNA testing for fetal aneuploidy and beyond: Clinical integration challenges in the United States context Human Reproduction. 2012:3123-3131.
  43. Sayres LC, Allyse M, Goodspeed T, Cho MK. In the public interest? Consequences of broad patenting and restrictive licensing for cell-free fetal DNA testing Science Translational Medicine.2012;
  44. Sayres LC, Allyse M, Cho MK. Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy. Genome Medicine.2012;49.
  45. Tobin SL, Cho MK, Lee SSJ, Magnus D, Allyse M, Ormond KE, Garrison N. Customers or Research Participants? Guidance for Research Practices in Commercialization of Personal Genomics Genetics in Medicine. 2012:833-835.
  46. Allyse M, Karkazis K, Lee SSJ, Tobin SL, Greely HT, Cho MK, Magnus D. Informational Risk, Institutional Review, and Autonomy in the Proposed Changes to the Common Rule IRB: Ethics & Human Research. 2012.
  47. Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation Prenat Diagnosis.2011;1070-6.
  48. Allyse M, Milner LC, Cho MK. Ethics watch: the G.I. genome: ethical implications of genome sequencing in the military Nature Reviews Genetics. 2011; Ethics watch:589.
  49. Allyse M. Embryos, Ethics and Expertise: the emerging model of the scientific research ethics regulator Science and Public Policy. 2010:597-610.